http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210135838-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70596 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 2020-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210135838-A |
| titleOfInvention | Pd-1 variants with increased binding to pd-l1 |
| abstract | The present invention relates to a PD-1 mutant having increased binding affinity to PD-L1 and aglycosylation characteristic, and the PD-1 mutant of the present invention has significantly increased PD-L1 and Because it has binding power and is a glycosylated mutant, but has improved binding power and stability, it is possible to simultaneously overcome the problem of low binding force of conventional PD-1 to PD-L1 and the problem of glycan heterogenity of protein therapeutics. It is inexpensive and easy to mass-produce, and there is an effect that it is possible to manufacture biopharmaceuticals without problems due to cell lines, culture processes, and purification processes. |
| priorityDate | 2020-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 215.